Kjeldahl method raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-04 and is reviewed periodically as new material appears.
Enzyme choice, pH, temperature, time, and substrate concentration influence the resulting peptide distribution. Endopeptidases cut internal peptide bonds, while exopeptidases remove terminal amino acids and can reduce bitterness. Manufacturers may combine enzymes or use membrane filtration to select peptide size ranges. A higher degree of hydrolysis generally means more small peptides and free amino acids, but it does not by itself define biological activity or nutritional quality. Batch-to-batch variation arises from raw whey composition, enzyme specificity, and processing parameters, so specification ranges are common in commercial supply.
Dried hydrolysate powders are usually off-white to pale yellow and are marketed as free-flowing powders or liquid concentrates. They are used in foods, beverages, and specialized nutrition products where rapid dispersion or reduced allergenicity is desired, although residual allergenic epitopes can remain depending on hydrolysis extent. The term hydrolysate does not imply a single molecular weight cutoff or a guaranteed clinical effect. Labels may state degree of hydrolysis, protein content, or peptide length profile, but analytical definitions vary across suppliers and jurisdictions.
Degree of hydrolysis is commonly estimated by titrating liberated carboxyl groups, measuring soluble nitrogen in trichloroacetic acid, or using o-phthaldialdehyde assays. Molecular weight distribution is often examined by size-exclusion chromatography, sodium dodecyl sulfate polyacrylamide gel electrophoresis, or mass spectrometry. These methods answer different questions: titration estimates bond cleavage, while chromatography describes peptide size ranges. Because no single reference method is universally applied, values reported by different laboratories may not be directly comparable. Method details such as calibration standards and sample preparation strongly influence results.
Routine quality control for hydrolysate powders includes total nitrogen or protein content by Kjeldahl or Dumas combustion, moisture by oven or Karl Fischer titration, ash, and mineral profiles. Microbiological tests typically cover total aerobic counts, yeasts, molds, and specified pathogens according to regional food safety rules. Amino acid analysis can quantify free amino acids and peptide-bound residues after hydrolysis. For products intended for special populations, additional tests may target residual lactose, fat, or specific allergenic proteins. Specifications are set by the manufacturer and may exceed general food-grade requirements.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow powder | Color varies with raw whey, filtration, and drying conditions. |
| Protein content | 70–90% dry basis | Depends on filtration, hydrolysis, and concentration steps. |
| Degree of hydrolysis | Often 5–30% | Higher values indicate more cleaved peptide bonds and often more bitterness. |
| Solubility | High in water at common food pH | Small peptides and free amino acids dissolve readily. |
| Common synonyms | Hydrolyzed whey protein; whey hydrolysate | Informal labels may omit the protein source or hydrolysis method. |
Whey protein hydrolysate is a dairy ingredient made by breaking peptide bonds in whey proteins. Enzymes such as proteases, or in some processes acid or heat, cleave the protein chains into shorter peptides and free amino acids. The starting material may be sweet whey, acid whey, whey protein concentrate, or whey protein isolate. Because raw materials and reaction conditions differ, the final mixture is not a single uniform substance. Its peptide profile, mineral content, and residual lactose depend on the source and the processing steps used.
Production typically begins with pasteurization and concentration of whey. A protease is added under controlled temperature and pH, and the reaction is stopped by heat or pH change when the target extent of cleavage is reached. Ultrafiltration or diafiltration may remove enzymes, salts, and small molecules. The liquid is then spray dried into a powder. Process parameters shape bitterness, solubility, and peptide size. Established control points include enzyme type, reaction time, and inactivation conditions. How these variables interact across large-scale batches remains an area of active process development.
Hydrolysates usually contain 70% to 90% protein on a dry basis, with variable ash, fat, and carbohydrate. Solubility in water is generally high over a broad pH range, though bitter notes can appear from exposed hydrophobic peptides. The powder tends to absorb moisture and may brown during prolonged warm storage. Applications span sports nutrition, clinical nutrition, infant formulas, and flavor systems. Regulatory status and labeling rules differ by country. A key open question is whether a given peptide profile reliably predicts functional or sensory behavior across different food matrices.
Laboratories characterize hydrolyzed whey protein with several complementary assays. Total nitrogen methods, such as Kjeldahl or Dumas, estimate protein content using a dairy conversion factor. Free amino group assays, including TNBS and OPA, track the extent of peptide-bond cleavage. Size-exclusion chromatography and reversed-phase HPLC reveal peptide size distributions and hydrophobicity. Mass spectrometry can identify specific peptides, while amino acid analysis quantifies individual residues. No single test captures every relevant property, so results are usually interpreted together with process records and specification limits.
Quality control checks identity, composition, and contaminants. Moisture, ash, fat, and carbohydrate are measured by standard methods, and microbiological limits are set for total counts, coliforms, and specific pathogens. Heavy metals and pesticide residues may be monitored depending on market requirements. Adulteration with intact whey protein or individual amino acids is possible, so peptide fingerprints and free amino acid profiles can help verify authenticity. Regulatory frameworks vary: some countries treat hydrolyzed whey as a conventional dairy ingredient, while infant formula uses face additional compositional rules. Which marker peptides best confirm source and processing remains an open analytical question.
Analytical testing for whey protein hydrolysate focuses on peptide size distribution, degree of hydrolysis, protein content, moisture, ash, and microbiological quality. Size-exclusion chromatography and mass spectrometry can characterize peptide profiles, while Kjeldahl or combustion methods estimate total nitrogen and protein. Amino acid analysis quantifies free and total amino acids. Because peptide mixtures are complex, no single method captures every property, and results can vary between laboratories. Standardized methods and reference materials help improve comparability, but full sequence-level characterization remains uncommon in routine quality control.
Regulatory treatment of whey protein hydrolysate depends on the country and intended use. In many jurisdictions it is regulated as a food ingredient or food for special dietary use, not as a drug. Labeling rules govern allergen statements, protein content claims, and ingredient names. Some markets have specific rules for infant formula ingredients, where hydrolysates may be used for particular dietary purposes. Regulations generally focus on safety, truthful labeling, and manufacturing standards rather than on therapeutic effects. Scientific questions about specific peptide activities remain an active area of research rather than a settled regulatory category.
== See also == The FASTQ format, used to represent DNA sequencer reads along with quality scores. The SAM and CRAM formats, used to represent genome sequencer reads that have been aligned to genome sequences. The GVF format (Genome Variation Format), an extension based on the GFF3 format.
On the morning of 8 September, representatives of the Fatherland Front - Kimon Georgiev, Nikola Petkov, Dimitar Neykov, Kiril Dramaliev and Dimo Kazasov - met with the Prime Minister, protesting the dispersal of opposition demonstrations in the previous days and demanding that rallies be allowed in the major cities. Kimon Georgiev hosted a meeting of the Fatherland Front's National Committee at 4 p.m. on 8 September. The government's composition was settled upon, and its policy text is approved. The composition of the future government and the new regents were specified at a meeting between Kimon Georgiev, Dobri Terpeshev, Nikola Petkov and Damyan Velchev at Georgiev's home at 4 pm on 8 September. It was agreed that the cabinet would include four representatives each of the BRP, Zveno and BZNS-Pladne, two of the BRSD and two independents, and that the prime minister would be Kimon Georgiev, a decision agreed with Soviet dictator Joseph Stalin. Georgiev spent the night of the coup with Damyan Velchev, Nikola Petkov, and Traicho Dobroslavsky at the home of Yanko Antonov near the Eagles Bridge - he was a neighbor of Peter Vranchev, in whose apartment the Communist leaders - Dobri Terpeshev, Anton Yugov, Georgi Chankov, Angel Tsanev, and Katya Avramova were at the time. The coup began at 2 a.m. on 9 September with the seizure of the War Ministry building. War Minister Ivan Marinov sided with the coup and issued the appropriate orders to the First Infantry Division and the School for Reserve Officers.
== Contributions == De made significant contributions to the recent understanding of cholera and related diarrhoeal diseases and set a permanent milestone in the modern view of diseases caused by bacterial exotoxins. Followed by the discovery of Vibrio cholerae in 1884 by Robert Koch, many works have been carried out all over the world to answer many questions related with its pathogenesis and mode of transmission in causing outbreaks. The seminal works of De in Calcutta (now Kolkata) during 1950–60 breached several qualms pertaining to the enteric toxin produced by bacteria including V. cholerae and Escherichia coli. Three of his works viz., ligated intestinal loop method (which was a reinvention of Violle and Crendiropoulo method in 1915, but De was unaware of this work and made an independent discovery) for studying cholera in rabbit model; ileal loop model to demonstrate the association of some strains of E. coli with diarrhoea and lastly but most importantly is his discovery of cholera toxin in 1959 in the cell-free culture filtrate of V. cholerae that stimulated a specific cellular response. As noted by Garfield in his 1986 tribute, De was the first to demonstrate that cholera bacteria secrete enterotoxin. This discovery eventually promoted research to find a treatment aimed directly at neutralising the cholera enterotoxin. De's paper "Enterotoxicity of bacteria-free culture-filtrate of Vibrio cholerae," while initially unrecognised, today is considered a milestone in the history of cholera research. Biochemist W. E.
Sources: en.wikipedia.org
Amorphous selenium has a low melting point, high vapor pressure, and uniform structure. These three properties allow quick and easy deposition of large-area uniform films with a thickness up to 1 mm at a rate of 1–5 μm/min. Their uniformity and lack of grain boundaries, which are intrinsic to polycrystalline materials, improve the X-ray image quality. Meanwhile the large area is essential for scanning the human body or luggage items. Selenium is less toxic than many compound semiconductors that contain arsenic or heavy metals such as mercury or lead. The mobility in applied electric field is sufficiently high both for electrons and holes, so that in a typical 0.2 mm thick device, c. 98% of electrons and holes produced by X-rays are collected at the electrodes without being trapped by various defects. Consequently, device sensitivity is high, and its behavior is easy to describe by simple transport equations.
== Success rate == Candidates for a new drug to treat a disease might, theoretically, include from 5,000 to 10,000 chemical compounds. On average about 250 of these show sufficient promise for further evaluation using laboratory tests, mice and other test animals. Typically, about ten of these qualify for tests on humans. A study conducted by the Tufts Center for the Study of Drug Development covering the 1980s and 1990s found that only 21.5 percent of drugs that started Phase I trials were eventually approved for marketing. In the time period of 2006 to 2015, the success rate was 9.6%. The high failure rates associated with pharmaceutical development are referred to as the "attrition rate" problem. Careful decision making during drug development is essential to avoid costly failures. In many cases, intelligent programme and clinical trial design can prevent false negative results. Well-designed, dose-finding studies and comparisons against both a placebo and a gold-standard treatment arm play a major role in achieving reliable data.
=== Congenital adrenal hyperplasia === In congenital adrenal hyperplasia, the adrenal cortex lacks appropriate corticosteroid synthesis, leading to excess adrenal androgens and affects female fetuses. There is an external masculinization of the genitalia in the female fetuses. Mothers of at risk fetuses are given dexamethasone at 6 weeks gestation to suppress pituitary gland release of androgens. If analysis of cffDNA obtained from a sample of maternal plasma lacks genetic markers found only on the Y chromosome, it is suggestive of a female fetus. However, it might also indicate a failure of the analysis itself (a false negative result). Paternal genetic polymorphisms and sex-independent markers may be used to detect cffDNA. A high degree of heterozygosity of these markers must be present for this application.
Sources: en.wikipedia.org
== Reform and replacement == The Local Transport Act 2008 reconstituted it as the Greater Manchester Integrated Transport Authority. The integrated transport authority was replaced by Transport for Greater Manchester in 2011, which is accountable to the Greater Manchester Combined Authority.
Chloral hydrate had some other important advantages that kept it in use for five decades despite the existence of more advanced barbiturates. It was the safest available sedative until the middle of the twentieth century, and thus was particularly favored for children. It also left patients much more refreshed after a deep sleep than more recently invented sedatives. Its frequency of use made it an early and regular feature in The Merck Manual. Chloral hydrate was also a significant object of study in various early pharmacological experiments. In 1875, Claude Bernard tried to determine if chloral hydrate exerted its action through a metabolic conversion to chloroform. This was not only the first attempt to determine whether different drugs were converted to the same metabolite in the body but also the first to measure the concentration of a particular pharmaceutical in the blood. The results were inconclusive. In 1899 and 1901 Hans Horst Meyer and Ernest Overton respectively made the major discovery that the general anaesthetic action of a drug was strongly correlated to its lipid solubility. However, chloral hydrate was quite polar but nonetheless a potent hypnotic. Overton was unable to explain this mystery. Thus, chloral hydrate remained one of the major and persistent exceptions to this breakthrough discovery in pharmacology. This anomaly was eventually resolved in 1948, when Claude Bernard's experiment was repeated.
K a = [ H + ] [ A − ] [ HA ] {\displaystyle K_{a}={\frac {{\ce {[H+] [A^{-}]}}}{{\ce {[HA]}}}}} The stronger of two acids will have a higher Ka than the weaker acid; the ratio of hydrogen cations to acid will be higher for the stronger acid as the stronger acid has a greater tendency to lose its proton. Because the range of possible values for Ka spans many orders of magnitude, a more manageable constant, pKa is more frequently used, where pKa = −log10 Ka. Stronger acids have a smaller pKa than weaker acids. Experimentally determined pKa at 25 °C in aqueous solution are often quoted in textbooks and reference material. Arrhenius acids are named according to their anions. In the classical naming system, the ionic suffix is dropped and replaced with a new suffix, according to the table following. The prefix "hydro-" is used when the acid is made up of just hydrogen and one other element. For example, HCl has chloride as its anion, so the hydro- prefix is used, and the -ide suffix makes the name take the form hydrochloric acid. Classical naming system:
Sources: en.wikipedia.org
Hydrolysate has been enzymatically or chemically cleaved into smaller peptides, whereas isolate is largely intact protein that has been filtered to high protein content. The two can share a dairy origin but differ in peptide length, taste, and functional behavior. Degree of hydrolysis is a common but not standardized descriptor.
Hydrolysis can reduce the size and number of allergenic epitopes, but it does not necessarily eliminate allergenic potential. Residual peptides may still bind immunoglobulin E in sensitive individuals. Products intended for allergen management are typically assessed by specific immunoassays and clinical criteria.
No. Degree of hydrolysis estimates the proportion of peptide bonds cleaved, while protein content measures total nitrogen or amino acid content. A high-protein hydrolysate can have a low or moderate degree of hydrolysis, and vice versa. Both values are useful but describe different properties.
Peptide size is commonly estimated by size-exclusion chromatography, gel electrophoresis, or mass spectrometry. These techniques separate or identify molecules according to mass or hydrodynamic volume. Results depend on calibration and method conditions, so they are best compared within the same analytical protocol.